Delivery Order SPE2DB25D2204-SPE2DB25FTGQW
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a $15,566.22 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL injectable medication. This firm fixed-price delivery order, issued on June 20, 2025, with an ultimate completion date of June 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The award was made through open competition with no set-aside designation, and performance will be based at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,075.18 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 ml pharmaceutical product. This firm fixed-price delivery order was competitively awarded without set-aside designation and carries an ultimate completion date of September 19, 2025. The award represents a continuation of services under AmerisourceBergen's broader contract vehicle with DLA, leveraging the company's established...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,058.52 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL injectable medication. Issued on August 14, 2025, with an ultimate completion date of August 15, 2025, this firm fixed-price contract requires performance at the company's Conshohocken, Pennsylvania location. The award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $19,218.06 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This is a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Actemra ActPen 162 mg/0.9 ml auto-injector pens with a ceiling value of $18,556.74. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 12, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- The Defense Logistics Agency awarded a delivery order valued at approximately $51,886 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen (162 mg/0.9 mL) pharmaceutical product, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract was issued on July 24, 2025, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The award includes no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $14,389.20 to AmerisourceBergen Drug Corp for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL injectable pens. This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The contract carries no set-aside designation, indicating it was competitively awarded...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGQWDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $14,597.43 firm fixed price delivery order on June 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL injectable medication. The contract is classified as a child award under a larger indefinite delivery vehicle and carries an ultimate completion date of June 18, 2025. This delivery order was competitively awarded with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Actemra, a specialty pharmaceutical used in rheumatoid arthritis and other inflammatory conditions, represents the type of critical medical commodity delivered through this strategic contracting vehicle to support Defense Health Agency and other federal healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.6k | 6/17/25 |